No just generally addressing that little swipe on the 1.5b is overvalued remark. If revenue was on the horizon for just one of the two big indicators would be a 10b market cap easy. Now I know YOU know, as a doctor and scientist and avid watcher of biotech companies, know that not meeting primary endpoints does not necessarily mean a definitive no to commercialization. You are playing funny buggers, or at least again far too much so as a non holder posting on a Sunday morning...
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-254
-
- There are more pages in this discussion • 170 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.015(1.29%) |
Mkt cap ! $1.347B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.20 | $1.15 | $4.551M | 3.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 98246 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 19079 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |